The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study
- Conditions
- Complement AbnormalityPeripheral Blood Mononuclear CellsCovid19
- Registration Number
- NCT05258643
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Brief Summary
The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained. Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection.
Sample storage and subsequent use in fundamental research will be performed at VUB Neuro-Aging and Viro-Immunotherapy.
Additionally, medical records of UZ Brussel will be searched and epidemiological, clinical, radiological, and biological data of the selected patients will be obtained at the diagnosis time point and during follow-up.
Healthy volunteers will be recruited as well in the current study, as a comparison arm, after informed consent is obtained.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
- Positive nasopharyngeal reverse transcriptase-polymerase chain reaction for SARS-Coronavirus-02
- Signed inform consent
Healthy Volunteers
Inclusion Criteria:
- Signed inform consent
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Difference in complements or peripheral blood mononuclear cells between CoViD-19 patients and controls up to 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
UZ Brussel
🇧🇪Jette, Brussels, Belgium
UZ Brussel🇧🇪Jette, Brussels, BelgiumMarco MorettiContact